RecruitingNCT05601856
Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers
Sponsor
University of Virginia
Enrollment
104 participants
Start Date
Dec 15, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Spousal caregivers of Alzheimer's Dementia (AD) patients have an elevated risk of developing AD in the future. Past studies have shown the presence of serum indicators correlated with gut biome dysfunction in AD patients. We hypothesize that the same gut biome dysfunction may be present in spousal caregivers of AD patients.
Eligibility
Min Age: 65 YearsMax Age: 90 Years
Inclusion Criteria4
- patients with AD whose clinical dementia rating (CDR) is \> 1
- Spouses of Patients in the above group Or
- Healthy adult unrelated to groups 1 and 2, with no history of dementia And
- Regardless of the grouping, the prospective subject must be between 65 and 90 years old
Exclusion Criteria15
- Familial Alzheimer's Disease (AD)
- Severe cardiovascular disease
- Severe respiratory system disease
- Severe liver disease
- Severe kidney disease
- Severe central nervous system diseases
- Having a lifespan of fewer than 3 months
- History of psychiatric illness
- Major neurological diseases other than AD
- Current use of corticosteroids, antibiotics, or bowel motility modification agents
- Any history of Alcoholism or illicit drug dependence
- Previous inclusion in this study
- Difficulty with follow-up or poor compliance
- Severe hearing impairment
- Severe vision impairment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05601856
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787278 locations